Service in 1950 and later undertaken also at the Arctic Investigations Program of the Centers for Disease Control in Anchorage. Consequently, the investigations concerning E. multilocularis and AHD have continued without interruption for -40 years, and some of the same personnel have been involved for all or most of that period. Aside from basic biological studies, major aspects of this study have included clinical chemotherapy trials and the development of screening and preventive programs [3] .
During the early years of this experience, most of the patients with AHD were admitted to the hospital with an abdominal mass or symptoms related to the primary hepatic lesion. For some patients the initial diagnosis was made on the basis of a positive screening serology with use of the indirect hemagglutination method. In 1985 an improved serological technique with use of a specific antigen of E. multilocularis was introduced [4, 5] ; and in 1988 field trials were initiated in which a portable ultrasonography (US) unit was used for screening in four high-risk villages, which resulted in the diagnosis of four active cases at an early stage of development. Another result of the improved method of screening was the identification of patients with a number of small, calcified hepatic lesions that on further study were found to represent lesions in which the larval cestode had died [6] . Five of these lesions were resected to confirm the diagnosis and to permit testing for viability. Thus far, 26 such cases have been identified and the patients received a clinical diagnosis of inactive AHD; in 12 cases serologies were positive and in 14 the diagnosis was based primarily on the results of computed tomography (CT) or US findings. All such inactive cases are still under investigation and will not be considered further here. The 44 locally acquired cases of active AHD diagnosed in North America form the basis for this review.
After publication of the report of Heath and Chevis [7] , widespread interest developed in the use of benzimidazole compounds for the treatment of hydatid disease. Clinical trials of both mebendazole and albendazole have been conducted; however, the results have been inconsistent. Some authors have reported a poor outcome with these drugs in the treatment of cystic hydatid disease [8-1 1], while others have obtained more optimistic results with regard to the treatment of this condition or AHD [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The purpose of this paper is to review in detail our 17-year experience with chemotherapy for AHD in Alaska and to present the data that have led us to conclude that E. multilocularis can be eradicated by treatment with compounds of the benzimidazole group.
Methods
The records of all 44 patients with active AHD were reviewed. Tissues were obtained from 14 patients on 26 occasions for in vivo assays for viability. Chemotherapy has been offered to all patients since 1974 (mebendazole through 1984 and albendazole since 1985). Patients scheduled for surgery usually received two or three 28-day courses of albendazole before resection or biopsy of tissues that were to be tested for viability was performed. After a diagnosis of AHD was made and clinical and laboratory data were recorded, chemotherapy was initiated as follows: patients re- (table 1) . These parameters were based empirically on results of bioassays performed before 1985 (for all patients treated for >24 months, with one exception, the results were negative) [26] . Since vesicles of the larval cestode in host tissue remain infective for > 1 week when stored under refrigeration, vesicles obtained at autopsy 2-3 days postmortem were suitable for testing. Untreated patients for whom in vivo tests were performed served as historical controls. Patients who received insufficient chemotherapy, as defined above, are for present purposes described as undertreated. Twelve tests were performed for 10 untreated or undertreated individuals.
The reliability of the in vivo test depends on whether an adequate quantity of membranes from the patient's tissues has been obtained. Material obtained by needle biopsy is the least reliable, since few, if any, membranes may be present. In contrast to tissues of E. multilocularis that are used for maintaining isolates in the laboratory, also transferred by intraperitoneal inoculation, those obtained from patients are difficult to quantify for in vivo tests. Fully developed larval cestodes from rodents consist of a dense aggregation of microcysts with abundant protoscolices and little or no host tissue. Consequently, uniform 0. l-g samples are readily obtainable. In humans, however, sterile vesicles (lacking protoscolices) that are usually of small size are dispersed in a dense matrix of collagen that has replaced hepatic tissue. In collecting material for inoculation, slices of the lesion are examined for cavities containing membranes (figure 1), which are translucent and often folded [28] . The membranes are removed by means of fine-pointed forceps and placed in saline, after which aliquots are prepared for inoculation into the rodents (three rodents were routinely inoculated, unless the quantity of membranes was insufficient).
When normally developed larval E. multilocularis consists of great numbers of closely apposed, interconnected vesicles, each made up of an external nonviable layer, the laminated membrane, and an internal layer of germinal tissue from which brood capsules and protoscolices arise. When found 
Clinical Experience
The effect that chemotherapy has had on the clinical course of the disease was also evaluated. Among 31 patients for whom the diagnosis was made before 1974, six were cured with surgical resection and two underwent incomplete resections. Twenty-three patients with nonresectable disease initially received no chemotherapy. Early in this experience five cases were excluded from analysis because clinical data were insufficient for assessment (data on these five cases were included only with regard to survival). Two cases in which incomplete resections were performed and one recent case (case 42 in which severe undertreatment occurred because of noncompliance with therapy) are added to the remaining 18 untreated cases to give a total of 21 patients who had active untreated or undertreated lesions and who were observed over time. They serve as the historical controls to be compared with 13 patients who received chemotherapy (table 2). (Eleven active cases were diagnosed after 1974 when chemotherapy trials were initiated; of these, data from three are not included because the patients died of causes unrelated to AHD before they had received 2 years of mebendazole therapy.) Five patients in the untreated group eventually received chemotherapy (cases 1, 2, 3, 30, and 42) , and data from these cases appear in both the treated and untreated categories, resulting in analysis of 34 cases.
In this study the sizes of untreated hepatic lesions were largely determined during physical examination by measuring the palpable liver edge or hepatic mass below the costal margin. Alive.
End-stage disease was defined as that involving a massive lesion (diameter, > 15 cm or liver edge > 11 cm below the costal margin), and extension of disease was defined as that causing obstruction of the inferior vena cava, major hepatic bile ducts, or portal vein or the development of fistulae or distant metastases [26] . Progression of disease is severe and unequivocal: if a patient had end-stage disease before the start of chemotherapy and died of late complications of AHD, the case was not described as showing severe progression or as developing end-stage disease while receiving chemotherapy.
Results
Long-term mebendazole therapy. Eight patients were treated with mebendazole for >2 years. Of these, tissues were obtained for viability studies from six. A needle biopsy specimen from one patient (case 4) was positive in 1978, 48 months after therapy was initiated. Tissues were evaluated on 10 other occasions from these six patients. Five specimens were obtained at autopsy and five during surgical exploration. The autopsy findings and in vivo results for two of the patients have been previously reported [26] . Table 3 [27] . Although the initial in vivo test performed after 3 months of therapy with albendazole was negative, the case was complicated by both noncompliance and low serum albendazole levels of 3 10 ng/mL. She had received no more than 1.5 months of appropriate therapy when reactivation with growth of the lesion to 10 cm occurred. A second series of treatments for 9 months (600 mg b.i.d.) arrested growth for 16 months, and peak serum albendazole levels of 1,320 and 2,120 ng/mL were attained. However, the lesion then increased in size to 11 cm, and results of an in vivo assay were positive. A third series of treatments with albendazole for 9 months was started in February 1990, followed by longterm mebendazole therapy. The size of the lesion has been stable for 21 months and the patient remains asymptomatic, but the long-term prognosis is not clear. Although we believe that this patient has been taking her drugs as directed since 1988, she, very unlike the other patients, has been quite unreliable in many ways. In addition, other factors such as possible drug resistance or inadequate host immunity must be considered as contributing to this delayed treatment failure. This is the only case, in our experience, in which the larval cestode grew during administration of chemotherapy. While it is too early to fully assess this case, we will consider it at this time as one in which inappropriate therapy was administered.
Vole cases (cases 1, 3, and 4) . However, these changes were unrelated to the effect of chemotherapy and have been excluded little is known regarding the natural history of AHD that it is difficult to speculate on what the eventual survival time will be among the treated patients. Nevertheless, since all have remained asymptomatic and, with the exception of the one noncompliant patient, no enlargement of the lesion has been discerned for a period averaging nearly 5 years, we believe that they, as a group, can be expected to survive well beyond the untreated patients. The 5-year survival rate was 56% for the untreated group and 90% for the treated groups. The 10-year survival rate among untreated patients with a diagnosis of AHD before 1981 was 3 1% (five of 16) and 75% (six of eight) in the treated groups. Ammann et al.
[23] also reported improved survival among 60 patients treated with long-term mebendazole therapy. The 5-year survival rate for these patients was 96%, and at 10 years, 84%. For untreated historical controls the 10-year survival rate was <10%.
Discussion
The natural clinical course of untreated AHD has a wide spectrum of presentations. Some lesions appear to respond to host defenses and are spontaneously cured [6] . More characteristically, however, the course of untreated AHD is that of relentless growth with invasion of vital structures, resulting in obstruction of the inferior vena cava, major bile ducts, or portal blood flow; terminal anasarca often develops. A massive liver or a greatly distended abdomen due to ascites characteristically develops. Before we conducted our first chemotherapy trial in late 1974, 67% (16 of 24) of our cases developed along this dreadful course (three of the first four patients treated with mebendazole had marked hepatomegaly when treatment was initiated). In others, fatal brain metastases or extensive pulmonary metastases occurred. One may consider this progressive but lingering fatal course to be the "classic" clinical course of active, untreated AHD.
The untreated AHD lesion consists of extremely dense fibrous tissue in which microcysts of the larval E. multilocularis are scattered [ However, humans have a much more active immunologic response to E. multilocularis than do rodents, as evidenced by the absence of protoscolices together with the marked degree of necrosis and scarring associated with the lesion that develops in humans. The not-infrequent occurrence of spontaneous cure with death of the larval cestode also indicates a good host defense in humans [6] . Thus, the combination of an active immunologic response and the effect of chemotherapy could result in death of the parasite in humans but not in rodents.
The appearance of a typical E. multilocularis lesion on CT or an abdominal roentgenogram has been described as being of mixed density, with areas of calcification interspersed with radiolucent or hypodense areas [32, 36] . This finding suggests that these lesions continue to proliferate peripherally, with healing in deeper tissues, death of the larval cestode, and increasing calcification. given for >2 years. Only three patients in the Swiss study had been treated for this long, and the test was negative for one of them.
The number of in vivo tests for which consistently negative results were obtained for mebendazole-treated patients (table 1), together with supporting clinical observations, offers convincing evidence that long-term mebendazole therapy has been parasiticidal. The limited number of vole tests performed for albendazole-treated patients and the shorter time of follow-up make the interpretation of the results for this group more difficult. However, in assessing these results, the following considerations should be kept in mind. The objective of these chemotherapy trials was, and continues to be, to learn as much as we can as quickly as possible about the therapeutic dosage of albendazole. We were aware that while patients were receiving mebendazole therapy, the parasite had survived as long as 48 months and that albendazole was often hepatotoxic; thus it was important to determine the shortest duration of administration of the drug for effective therapy. The first two vole tests gave negative results after only 2 and 3 months of therapy. More recent results indicate that the parasite, at least in case 60, survived 3 months of treatment. The positive vole tests in cases 42 and 60 should not be viewed so much as reflecting the failure of albendazole therapy but rather that the minimum treatment time should be >3 months.
In view of the in vivo results together with the clinical observations on the four compliant patients who received albendazole, very impressive results were obtained that suggest that the long-term prognosis for these patients is excellent (table 4). In case 39 the negative vole test and negative postoperative serologies over 6.6 years are significant. The apparent reduced viability of the larval cestode with growth in only one of three injected voles in case 60 suggests that 3 months of chemotherapy had severely injured the parasite. In cases 51 and 53, no posttreatment tissue was available for in vivo studies. The clinical results, as reflected in the results of five serial CT studies, however, are very encouraging. In both cases, not only was there no growth of the lesion, but there has been a significant reduction in the amount of hypodense tissue; the calcifications have become more confluent and solid during the 3.3 and 4.7 years of observation. We are certain that in each case the lesion was active at the time chemotherapy was started because the pretreatment vole test in case 51 was positive and, in both cases, changes in the appearance on computed tomograms were observed over time. Had the lesion been dead, no change in appearance would have been expected. The advantages of a drug that is effective over months rather than years are so great that we feel continued emphasis on clinical trials with albendazole is justified.
We have presented our experience with albendazole for the treatment of AHD as well as evidence that it may be hepatotoxic in some cases [27] . Certainly, the need for close monitoring of all patients who receive the drug must be clearly recognized. There continues to be an urgent need to learn as much as possible from each new case of AHD. Our experience with this disease has persuaded us that postponing surgery adds little risk provided the patient is receiving appropriate chemotherapy. It is suggested that for all newly diagnosed cases, both of resectable and nonresectable lesions due to E. multilocularis, 4-6 months of preoperative therapy with albendazole be administered and be followed by viability studies on subsequent biopsy specimens or resected tis-sues. A drug-free interval of 1 week before surgery is suggested so that residual drugs in the tissue do not give false in vivo assay results (this precaution was taken in case 60 but not in previous studies). Although the therapeutic serum level of albendazole is not known, the dose should be adjusted to assure an albendazole sulfoxide serum level of -~ 1,000 ng/mL. Until therapeutic parameters are better defined, we feel that, following biopsy or resectional surgery, additional chemotherapeutic coverage with albendazole for a total of at least 12 months is advisable.
Summary
Most of these data suggest that the outcome of chemotherapy extends well beyond that of a favorable or parasitistatic effect. Some of the most convincing evidence for the successful killing of the larval E. multilocularis as a result of chemotherapy includes the following findings.
( (5) In case 5, followed for 15 years, a 7 X 10-cm hepatic lesion, initially proven to be active by the vole test, has demonstrated decreasing hypodense areas, increasing calcifications, and no growth on serial CT studies over a 10-year period. The EM2 serologies, consistently strongly positive for 10 years, have been negative on each of seven occasions since 1986 even though the patient has received no chemotherapy for 6.7 years.
(6) Among five patients treated with albendazole, vole viability assays were negative after 2 months of therapy for one patient; in two patients there was evidence of significant damage to the larval cestode after 1.5 and 3 months of therapy, respectively. For two other patients with resectable lesions who were treated with only albendazole, serial CT studies showed a decrease in the extent of radiolucent areas, an increase and confluence of calcifications, and no growth over 4 years. Although more time is required to fully assess this group of patients, the findings are consistent with a lethal effect of albendazole therapy.
(7) A comparative review of treated vs. untreated cases revealed striking differences. Among 21 untreated cases there was severe progression of disease in 95%, end-stage disease developed in 81%, and all patients have died after an average survival time of only 5.3 years. Among 13 treated cases, excluding the noncompliant patient, none showed severe progression or developed end-stage disease; in 77% there was objective evidence of a favorable response to therapy, and survival time is now 13.6 years (eight patients are still living and asymptomatic).
